Arch Therapeutics Inc. to Present at the Third Annual Marcum MicroCap Conference
May 27 2014 - 8:00AM
Marketwired
Arch Therapeutics Inc. to Present at the Third Annual Marcum
MicroCap Conference
WELLESLEY, MA--(Marketwired - May 27, 2014) - Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences
company and developer of the AC5 Surgical Hemostatic Device™, a
novel product aimed at controlling bleeding and fluid loss in order
to provide faster and safer surgical and interventional care,
announced today that it will be a featured presenter at the 3rd
Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New
York City.
At the Third Annual Marcum MicroCap Conference to be held at the
Grand Hyatt New York Hotel in New York City on Thursday, May 29,
Dr. Norchi will present in the Winter Garden Room at 9:00 am ET
(Slot 1). The presentation will be available via a live webcast,
which can be accessed here: http://wsw.com/webcast/marcum2/arth.
This webcast will be archived for 90 days following the live
presentation.
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, under-followed public companies with less
than $500 million in market capitalization.
For more information or to register, please visit the conference
website at http://www.marcumllp.com/microcap.
About Arch Therapeutics, Inc. Arch Therapeutics, Inc. is a
medical device company developing a novel approach to stop bleeding
(hemostasis) and control leaking (sealant) during surgery and
trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5 Surgical
Hemostatic Device™, is being designed to achieve hemostasis in
minimally invasive and open surgical procedures.
Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements This news
release contains "forward-looking statements" as that term is
defined in Section 27(a) of the Securities Act of 1933, as amended,
and Section 21(e) of the Securities Exchange Act of 1934, as
amended. Statements in this press release that are not purely
historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, references to novel technologies and methods,
our business and product development plans and projections, or
market information. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or
technologies and operating as a development stage company, our
ability to retain important members of our management team and
attract other qualified personnel, our ability to raise the
additional funding we will need to continue to pursue our business
and product development plans, our ability to develop and
commercialize products based on our technology platform, and market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at
www.sec.gov.
On Behalf of the Board, Terrence W. Norchi, MD Arch
Therapeutics, Inc.
Contact: ARTH Investor Relations Toll Free: +1-855-340-ARTH
(2784) (US and Canada) Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Dec 2023 to Dec 2024
